 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...3456789101112131415» |
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Long-term outcome after thoracoscopic cardiac sympathectomy for refractory ventricular tachyarrhythmia storm. (Pubmed Central) - Apr 6, 2022
A man in his 40s presented with an acute anterior wall myocardial infarction (MI) 6 hours after symptom onset to a non-percutaneous intervention enabled hospital and underwent thrombolysis with tenecteplase...Although the patient remained free of VT/ventricular fibrillation (VF) for 48 hours, he had an episode of VF subsequently. A decision for bilateral surgical video assisted thoracoscopic cardiac sympathetic denervation was taken and the patient remained free of ventricular tachyarrhythmias after the procedure until.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Sex Differences in the Norwegian Tenecteplase Trial (NOR-TEST). (Pubmed Central) - Apr 5, 2022
Women were in number underrepresented in the NOR-TEST trial. The included women had a lower cardiovascular risk factor burden and more severe strokes.
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
@jposas moderating @danackerman and @PierreFayad3 on the eternal question: #alteplase or #tenecteplase? #AANAM (Twitter) - Apr 5, 2022
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke https://t.co/StbLuRqgVt via @JAMANetworkOpen part of @JAMANetwork (Twitter) - Apr 2, 2022
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion: CHABLIS-T: CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase (clinicaltrials.gov) - Mar 31, 2022
P2, N=86, Completed, Sponsor: Huashan Hospital
The included women had a lower cardiovascular risk factor burden and more severe strokes. Active, not recruiting --> Completed
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Tenecteplase should be routinely used for thrombolysis in acute ischemic stroke: Yes (HALL D) - Mar 26, 2022 - Abstract #CONy2022CONy_463;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Tenecteplase should be routinely used for thrombolysis in acute ischemic stroke: No (HALL D) - Mar 26, 2022 - Abstract #CONy2022CONy_462;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Tenecteplase should be routinely used for thrombolysis in acute ischemic stroke (HALL D) - Mar 26, 2022 - Abstract #CONy2022CONy_461;
Other studies suggest better recanalization rates with Tenecteplase, perhaps due to greater fibrin specificity. However, in most countries this remains an off-label Treatment.
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Acute Treatment of Ischemic Stroke. (Pubmed Central) - Mar 24, 2022
Current controversies and ongoing trials within endovascular treatment are also detailed. Case presentations are included to provide clinical context and the application of data to practice.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
MAJOR BLEEDING OF TENECTEPLASE VERSUS ALTEPLASE IN ACUTE ISCHEMIC STROKE ([VIRTUAL]) - Mar 23, 2022 - Abstract #SCCM2022SCCM_1781;
Case presentations are included to provide clinical context and the application of data to practice. Tenecteplase had similar rates of major bleeding versus alteplase in the treatment of acute ischemic stroke.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Tenecteplase versus alteplase for large vessel occlusion recanalization (T-FLAVOR): Trial protocol. (Pubmed Central) - Mar 19, 2022
T-FLAVOR may help determine if tenecteplase should be recommended as a routine clinical strategy before MT for Japanese stroke patients. jRCTs051210055.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ADDITIONAL INTRAVENOUS THROMBOLYSIS WITH TENECTEPLASE FOR ACUTE ALTEPLASE-RESISTANT MEDIUM VESSEL OCCLUSION STROKES (E-Poster Area) - Mar 18, 2022 - Abstract #ESOC2022ESOC_1744;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
FIBRINOLYTIC CAPACITY AND THE IN VIVO RESPONSE TO TPA VARIES OVER 100-FOLD IN PATIENTS WITH ACUTE ISCHAEMIC STROKE () - Mar 18, 2022 - Abstract #ESOC2022ESOC_1686;
The basis for this variation in plasmin generating capacity is unclear but may partly explain the clinical variation in tPA thrombolysis. TNK administration produces less systemic plasminogen activation and preserves fibrinogen.
- || Aggrastat (tirofiban) / Correvio, Medicure, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Yes, I wasn't satisfied with 15mg of alteplase (tenecteplase not available), so I've done Tirofiban, the dose of 30 minutes I did IC through MC. (Twitter) - Mar 17, 2022
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P2 trial: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II） (clinicaltrials.gov) - Mar 16, 2022
P2, N=225, Active, not recruiting, Sponsor: Beijing Tiantan Hospital
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
TWIST (TENECTEPLASE IN WAKE-UP ISCHAEMIC STROKE TRIAL) (Amphithéâtre) - Mar 12, 2022 - Abstract #ESOC2022ESOC_1635;
We examined the efficacy and safety of treatment with tenecteplase in 578 patients selected by non-contrast CT. Further conclusions will be presented at the conference.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Should clinical practice change towards tenecteplase? (Salon Pasteur) - Mar 12, 2022 - Abstract #ESOC2022ESOC_1397;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
THE MELBOURNE MOBILE STROKE UNIT TENECTEPLASE VERSUSALTEPLASE FOR STROKE THROMBOLYSIS EVALUATION TRIAL IN THE AMBULANCE (TASTE-A) (Amphithéâtre) - Mar 12, 2022 - Abstract #ESOC2022ESOC_1099;
P2
In the MSU environment, tenecteplase (TNK) offers practical benefits as it is administered as a single bolus rather than a one-hour infusion like alteplase (tPA). To be Determined.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
TENECTEPLASE VERSUS ALTEPLASE FOR MANAGEMENT OF ACUTE ISCHEMIC STROKE (NOR-TEST 2 PART A): A PHASE 3, RANDOMISED, OPEN-LABEL, BLINDED ENDPOINT TRIAL (Amphithéâtre) - Mar 12, 2022 - Abstract #ESOC2022ESOC_1097;
P3
The study could not demonstrate that 0.4 mg/kg tenecteplase is non-inferior to alteplase in moderate or severe ischemic stroke. Future stroke trials should assess a lower dose of tenecteplase versus alteplase in patients with moderate or severe stroke.EudraCT No 2018-003090-95.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ALTEPLASE COMPARED TO TENECTEPLASE (ACT) RANDOMIZED CONTROLLED TRIAL (Amphithéâtre) - Mar 12, 2022 - Abstract #ESOC2022ESOC_1087;
Future stroke trials should assess a lower dose of tenecteplase versus alteplase in patients with moderate or severe stroke.EudraCT No 2018-003090-95. Results from the AcT trial will provide real world evidence regarding effectiveness of intravenous tenecteplase vs. alteplase in patients with acute ischemic stroke eligible for intravenous thrombolysis.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
TREATMENT TIMES, FUNCTIONAL OUTCOME AND HEMORRHAGE RATES AFTER SWITCHING TO TENECTEPLASE FOR STROKE THROMBOLYSIS A SUBGROUP STUDY OF THE TETRIS REGISTRY (Forum 1) - Mar 12, 2022 - Abstract #ESOC2022ESOC_1021;
Results from the AcT trial will provide real world evidence regarding effectiveness of intravenous tenecteplase vs. alteplase in patients with acute ischemic stroke eligible for intravenous thrombolysis. Switch from alteplase to tenecteplase reduces process times and may improve functional outcome, with similar safety profile.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
INTRAVENOUS THROMBOLYSIS WITH TENECTEPLASE VERSUS ALTEPLASE IN ACUTE ISCHEMIC STROKE PATIENTS WITHIN 4.5 HOURS FROM SYMPTOM ONSET: A PROPENSITY SCORE-MATCHED ANALYSIS FROM THE SITS-ISTR REGISTRY (Forum 1) - Mar 12, 2022 - Abstract #ESOC2022ESOC_1020;
Switch from alteplase to tenecteplase reduces process times and may improve functional outcome, with similar safety profile. In this study, IVT with tenecteplase was associated with more favorable 3-month clinical outcomes compared to alteplase in AIS patients.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
STROKE THROMBOLYSIS DURING THE COVID PANDEMIC IN INDIA - A TALE OF TWO WAVES & LESSONS LEARNT (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_160;
Thrombolysis during the pandemic has been a challenge in many ways especially in resource limited settings. This study shows that there needs to be a conscious and judicial transition towards tenecteplase during the pandemic, where healthcare workers are a precious resource too.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
VALIDATION OF ISCHEMIC STROKE MODELS FOR USE IN TRANSLATIONAL RESEARCH: IN VITRO FLOW AND IN VIVO RAT MODELS (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_149;
Higher clot reduction of tenecteplase vs alteplase in the in vivo model is due to prolonged half-life of tenecteplase in vivo. Our models could be suitable to predict thrombolytic efficacy in patients.
- Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
THE COMPARISON OF REVASCULARIZATION RATE IN STROKE WITH LARGE VESSEL OCLUSSION USING TENECTAPLASE VS ALTEPLASE (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_135;
Tenecteplase prior to thrombectomy is effective and achieves a high rate of recanalization in clinical practice in acute ischemic stroke patients with large-vessel occlusion. Our findings are in line with other published results.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
RANDOMIZATION TO ENDOVASCULAR TREATMENT ALONE OR PRECEDED BY SYSTEMIC THROMBOLYSIS WITH TENECTEPLASE IN ACUTE ISCHEMIC STROKE DUE TO LARGE INTRACRANIAL VESSEL OCCLUSION TRIAL -RESILIENT DIRECT-TNK (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_124;
Background and aims: Recently completed studies have suggested that direct endovascular treatment (without previous administration of alteplase) may be a non-inferior alternative to the combination of tPA and thrombectomy for patients with anterior proximal large vessel occlusion. Study will test the hypothesis that acute ischemic stroke treatment with anterior LVO < 4.5 hours from the onset of symptoms, the mechanical thrombectomy strategy preceded by TNK is superior to mechanical thrombectomy alone to achieve more favorable outcomes measuring by mRS scores at 90 days.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY - TENCRAOS: A PROSPECTIVE, RANDOMISED-CONTROLLED, DOUBLE-DUMMY, DOUBLE-BLIND PHASE 3 MULTI-CENTRE TRIAL NCT04526951) (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_122;
P3
Currently there are 6 countries activated for recruitment. We have recruited 8 patients so far, 6 in Norway and 2 in Finland.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ALTEPLASE-TENECTEPLASE TRIAL EVALUATION FOR STROKE THROMBOLYSIS (ATTEST 2) (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_120;
Superiority or non-inferiority of tenecteplase compared to alteplase would potentially extend thrombolytic treatment to a greater proportion of patients, simplify drug administration and reduce the need for mechanical thrombectomy. This trial will contribute to the optimisation of reperfusion strategies.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
EFFICACY AND SAFETY OF INJECTION TENECTEPLASE IN 4.5 TO 24 HOURS IMAGING ELIGIBLE WINDOW PATIENTS WITH ACUTE ISCHEMIC STROKE (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_99;
This trial will contribute to the optimisation of reperfusion strategies. Efficacy and safety of tenecteplase using the modified Ranking scale (mRS) score at Day 90 will be determined.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
RANDOMIZATION TO EXTEND STROKE INTRAVENOUS THROMBOLYSIS IN EVOLVING NON-LARGE VESSEL OCCLUSION WITH TNK (RESILIENT- EXTEND-IV) (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_63;
Study Objective: To evaluate the hypothesis thatintravenous thrombolysis with Tenecteplase (TNK) ata dose of 0.25 mg/Kg is superior to standard medicalmanagement in achieving more favorable outcomes according to the modified Rankin Scale scores at 90days in subjects presenting with acute ischemic stroke not related to a large vessel occlusion within 4.5-12hours from symptom onset...Interim Analyses Conducted: when the first 386 patients enrolled have completed their study involvement. Sample size: 642 patients.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ADDITIONAL INTRAVENOUS THROMBOLYSIS WITH TENECTEPLASE FOR ACUTE ALTEPLASE-RESISTANT MEDIUM VESSEL OCCLUSION STROKES (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_21;
For patients with IV alteplase-treated MeVO strokes without early recanalization, an additional-dose of tenecteplase appears safe, more effective than alteplase alone and an easy-to-implement therapeutic option for carefully selected cases. Further controlled studies are needed to confirm these promising findings.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
THROMBUS PERVIOUSNESS IN LARGE VESSEL STROKE AS A PREDICTOR OF OUTCOME TO TENECTEPLASE (E-POSTER LIBRARY) - Mar 12, 2022 - Abstract #ESOC2022ESOC_19;
These findings may be relevant for therapeutic decisions. Nevertheless, validation in a larger cohort is necessary.
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
P3 data, Journal: A Phase III, Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of Thrombolysis in Imaging-Eligible, Late-Window Patients to Assess the Efficacy and Safety of Tenecteplase (TIMELESS): Rationale and Design. (Pubmed Central) - Mar 11, 2022
P3
Safety will be evaluated via incidence of symptomatic intracranial hemorrhage, incidence and severity of adverse events and mortality rate. Results from TIMELESS will contribute to understanding of the safety and efficacy of tenecteplase administered 4.5-24 hours following symptom onset for patients with an ICA or MCA occlusion.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Using Real World Evidence to Generate Cost-Effectiveness Analysis of Fibrinolytic Therapy in Patients with ST-Segment Elevation Myocardial Infarction in a Limited Resource Country (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1732;
Results from TIMELESS will contribute to understanding of the safety and efficacy of tenecteplase administered 4.5-24 hours following symptom onset for patients with an ICA or MCA occlusion. In a resource-limited country like Thailand, tenecteplase is a cost-effective fibrinolytic drug for treatment of STEMI compared to streptokinase.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Is Neutrophilia a Risk Factor for Fast Stroke Progression in Large Vessel Occlusion? (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3748;
Rapid stroke progression as measured by presenting ASPECTS score may be associated with neutrophilia. Larger prospective clinical trials are needed to validate our results
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Pulmonary Arteriovenous Malformation (PAVM): An Uncommon Cause of Cryptogenic and Embolic Stroke of Undetermined Source (ESUS). (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3339;
In our patient, intracardiac shunt was initially proposed as the mechanism of stroke, however, further diagnostic testing confirmed extra-cardiac, intrapulmonary shunt from PAVM as primary mechanism. In the ESUS population without traditional neurovascular risk factors, a comprehensive workup that includes exclusion of less common pathology (i.e.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Unusual Multicompartmental Intracranial Hemorrhage After Tenecteplase Administration (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3079;
Patient's multicompartmental intracranial hemorrhages unrelated to area of infraction were unusual in the absence of any vascular lesions to predispose hemorrhage based on CT and conventional angiography. Further observational studies are warranted to evaluate similar complications of Tenecteplase administration and their occurrence rates.
- Integrilin (eptifibatide) / Takeda, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Real-World Bridging with Intra-arterial therapy is safe after Tenectplase in patients with Acute Ischemic Stroke (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3069;
Our small subset of early real-world experience demonstrates a higher rate of symptomatic transformation in bridging with TNK, when compared with Alteplase. Larger prospective studies are needed.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Initial Experience with Tenecteplase as the Intravenous Thrombolytic of Choice Before Mechanical Thrombectomy for Large Vessel Occlusion Acute Ischemic Stroke (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3067;
Intravenous TNK in patients with LVOAIS is feasible, safe and effective. In our cohort from “real world” patients, TNK was associated with lower need for thrombectomy, high recanalization rates and shorter hospitalization.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Failure of Tenecteplase in Maintaining Collateral Circulation in Large Vessel Occlusion Strokes (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_3065;
Poor correlation of collateral grade and TICI score may have implications of faster progression in AIS patients with LVO, receiving TNK, if recanalization is not achieved. Larger prospective studies are needed to evaluate the effect of TNK on collateralization.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Incidence of Access Site Complications in Patients Receiving Tenecteplase as Bridging Therapy to Endovascular Treatment (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2914;
Our single center experience with TNK outside of the clinical trial setting with concomitant use of other antithrombotics suggests safety of bridging strategy. Larger prospective ‘real-life’ studies are required to validate our findings.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Risk of Distal Embolization in Large Vessel Occlusion Strokes Treated with Tenecteplase (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2657;
The exclusion of tandem and/or ICA occlusions due to small sample size was a significant limitation of the study that affects generalizability to the strokes secondary to LVO. The trend towards statistical significance in higher distal embolization rates in subjects receiving TNK warrants larger, prospective studies to validate results.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Pediatric Cerebral Infarction associated with recent SARS-CoV-2 mild infection treated with intravenous thrombolysis and endovascular thrombectomy (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2654;
The AIS etiology in our case remains uncertain as abnormal laboratory findings do not explain this presentation. There is high clinical suspicion of an embolic event as possible explanation, possibly related to SARS-CoV-2 postinfectious stage.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Tenecteplase is Safe and Efficacious in Telestroke Patients with Confirmed Large Vessel Occlusions () - Mar 6, 2022 - Abstract #AAN2022AAN_1625;
There is high clinical suspicion of an embolic event as possible explanation, possibly related to SARS-CoV-2 postinfectious stage. Telestroke patients with confirmed LVO and treated with tenecteplase were found to have better 90 day outcomes compared to patients treated with alteplase, without increased complication rates.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Tenecteplase Versus Alteplase For Large Vessel Occlusion Recanalization: T-FLAVOR Trial (Hall B2, Poster Hall; Board No. CTP3) - Feb 22, 2022 - Abstract #ISC2022ISC_1748;
Trial status: Study start date is 1st Oct. 2021 and now recruiting.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Randomization To Endovascular Treatment Alone Or Preceded By Systemic Thrombolysis With Tenecteplase In Acute Ischemic Stroke Due To Large Intracranial Vessel Occlusion Trial -direct Thrombectomy Vs. Intravenous Tnk Plus Thrombectomy - RESILIENT DIRECT TNK (Hall B2, Poster Hall; Board No. CTP11) - Feb 22, 2022 - Abstract #ISC2022ISC_1731;
Outcome: The primary outcome will be the ordinal distribution from the modified Rankin scale score (mRS) at 90 days.Trial Status: Enrolling starting in November, 2021. Fourteen sites already IRB approved and ready for enrollment.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Randomization To Extend Stroke Intravenous Thrombolysis In Evolving Non-large VesselOcclusion With TNK (Resilient- Extend-IV) (Hall B2, Poster Hall; Board No. CTP10) - Feb 22, 2022 - Abstract #ISC2022ISC_1730;
The randomization employs a 1:1 ratio of intravenous thrombolysis with tenecteplase (TNK) versus placebo in patients who suffer a non-large vessel occlusion ischemic stroke between 4.5 and 12 hours from time last seen well (TLSW) and have evidence of salvageable brain tissue on perfusion imaging...Interim Analyses Conducted: when the first 386 patients enrolled have completed their study involvement. Sample size: 642 patients.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Meet the Expert: Stroke Imaging and Reperfusion: Tenecteplase, Thrombectomy and Time Windows (Live on Zoom) - Feb 22, 2022 - Abstract #ISC2022ISC_1697;
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
303 - Meet the Expert 4: Stroke Imaging and Reperfusion: Tenecteplase, Thrombectomy and Time Windows (Live on Zoom) - Feb 22, 2022 - Abstract #ISC2022ISC_1696;
The button/link to access the call/meeting will be available 15 minutes prior to the session start time. Come prepared with your questions!
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Tenecteplase Thrombolysis For Stroke Up To 24 Hours After Onset With Perfusion Imaging Selection (Hall D) - Feb 22, 2022 - Abstract #ISC2022ISC_1337;
P2
Trial Registration Number: NCT04086147 Background and Aims: Growing evidence supports Tenecteplase (TNK) is noninferior to alteplase in acute ischemic stroke, and even superior to alteplase in patients with large vessel occlusions within 4.5 hours of onset. To be determined.